doi:10.3969/j.issn.1004-583X.2025.12.014

Abstract

CLC Number:

R575.5
R692

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.12.014

https://www.lchc.cn/EN/Y2025/V40/I12/1130

References 60

[1]	Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.doi:10.1097/hep.0000000000000323. pmid: 36727674
[2]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5): 418-434.doi:10.3760/cma.j.cn501113-20240327-00163.
[3]	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.doi:10.1016/j.jhep.2020.03.039. pmid: 32278004
[4]	Mantovani A, Zusi C, Dalbeni A, et al. Risk of kidney dysfunction in NAFLD[J]. Curr Pharm Des, 2020, 26(10): 1045-1061.doi:10.2174/1381612825666191026113119.
[5]	Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease[J]. J Hepatol, 2020, 72(4): 785-801.doi:10.1016/j.jhep.2020.01.013. pmid: 32059982
[6]	Cheung A, Ahmed A. Nonalcoholic fatty liver disease and chronic kidney disease: A review of links and risks[J]. Clin Exp Gastroenterol, 2021, 14: 457-465.doi:10.2147/ceg.S226130. pmid: 34819740
[7]	Tao Z, Li Y, Cheng B, et al. Influence of nonalcoholic fatty liver disease on the occurrence and severity of chronic kidney disease[J]. J Clin Transl Hepatol, 2022, 10(1): 164-173.doi:10.14218/jcth.2021.00171. pmid: 35233386
[8]	Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease[J]. Nat Rev Nephrol, 2022, 18(4): 259-268.doi:10.1038/s41581-021-00519-y.
[9]	Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis[J]. Gut, 2022, 71(1): 156-162.doi:10.1136/gutjnl-2020-323082. pmid: 33303564
[10]	Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis[J]. Clin J Am Soc Nephrol, 2010, 5(12): 2166-2171.doi:10.2215/cjn.05050610.
[11]	Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis[J]. PLoS Med, 2014, 11(7): e1001680.doi:10.1371/journal.pmed.1001680.
[12]	Gofton C, Upendran Y, Zheng MH, et al. MAFLD: How is it different from NAFLD?[J]. Clin Mol Hepatol, 2023, 29(Suppl): S17-S31.doi:10.3350/cmh.2022.0367.
[13]	Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD[J]. Liver Int, 2020, 40(12): 3018-3030.doi:10.1111/liv.14675.
[14]	Su W, Chen M, Xiao L, et al. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease[J]. Front Public Health, 2022, 10: 1047794.doi:10.3389/fpubh.2022.1047794.
[15]	Liang Y, Chen H, Liu Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-year cohort study in China[J]. J Clin Endocrinol Metab, 2022, 107(1): 88-97.doi:10.1210/clinem/dgab641.
[16]	Kwon SY, Park J, Park SH, et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease[J]. Sci Rep, 2023, 13(1): 1796.doi:10.1038/s41598-023-27762-6. pmid: 36720976
[17]	孙铭辰, 赵翠荣, 卢翠翠, 等. 线粒体功能障碍在糖尿病肾病足细胞脂代谢中作用的研究现状[J]. 中国临床药理学杂志, 2024, 40(17): 2601-2605.doi:10.13699/j.cnki.1001-6821.2024.17.030.
[18]	Duan Y, Luo J, Pan X, et al. Association between inflammatory markers and non-alcoholic fatty liver disease in obese children[J]. Front Public Health, 2022, 10: 991393.doi:10.3389/fpubh.2022.991393.
[19]	Cai X, Sun L, Liu X, et al. Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease[J]. Ther Adv Chronic Dis, 2021, 12: 20406223211024361.doi:10.1177/20406223211024361.
[20]	Cao N, Liu X, Deng Y, et al. Reactive oxygen species/c-Jun N-terminal kinase/nuclear factor kappa-B signaling molecules are involved in pe-riodontitis-induced liver injury by regulating apoptosis[J]. Hua Xi Kou Qiang Yi Xue Za Zhi, 2022, 40(5): 532-540.doi:10.7518/hxkq.2022.05.005.
[21]	Kishi S, Nagasu H, Kidokoro K, et al. Oxidative stress and the role of redox signalling in chronic kidney disease[J]. Nat Rev Nephrol, 2024, 20(2): 101-119.doi:10.1038/s41581-023-00775-0.
[22]	Wang S, Jia Q, Liu X, et al. Hyperoside modulates bile acid and fatty acid metabolism, presenting a potentially promising treatment for non-alcoholic fatty liver disease[J]. J Adv Res, 2025.doi:10.1016/j.jare.2025.05.014.
[23]	Peiseler M, Schwabe R, Hampe J, et al. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits[J]. J Hepatol, 2022, 77(4): 1136-1160.doi:10.1016/j.jhep.2022.06.012. pmid: 35750137
[24]	Niu B, Liu J, Zhou H, et al. ACT001 alleviates MASLD through gut microbiota-bile acid-FXR axis in mice[J]. Ann Med, 2025, 57(1): 2580773.doi:10.1080/07853890.2025.2580773.
[25]	Sun DQ, Yuan F, Fu MZ, et al. Farnesoid X receptor activation protects against renal fibrosis via modulation of β-catenin signaling[J]. Mol Metab, 2024, 79: 101841.doi:10.1016/j.molmet.2023.101841.
[26]	Mitrofanova A, Merscher S, Fornoni A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease[J]. Nat Rev Nephrol, 2023, 19(10): 629-645.doi:10.1038/s41581-023-00741-w. pmid: 37500941
[27]	Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease[J]. J Clin Invest, 2020, 130(3): 1453-1460.doi:10.1172/jci134165. pmid: 31805015
[28]	Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD[J]. Diabetes Metab Syndr, 2020, 14(6): 1875-1887.doi:10.1016/j.dsx.2020.09.026. pmid: 32998095
[29]	Li M, Chi X, Wang Y, et al. Trends in insulin resistance:Insights into mechanisms and therapeutic strategy[J]. Signal Transduct Target Ther, 2022, 7(1): 216.doi:10.1038/s41392-022-01073-0.
[30]	Zhou B, Luo Y, Bi H, et al. Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11[J]. Cell Metab, 2024, 36(10): 2228-2244.e2227.doi:10.1016/j.cmet.2024.07.014. pmid: 39146936
[31]	Parwani K, Mandal P. Role of advanced glycation end products and insulin resistance in diabetic nephropathy[J]. Arch Physiol Biochem, 2023, 129(1): 95-107.doi:10.1080/13813455.2020.1797106.
[32]	Sebastian SA, Padda I, Johal G. Cardiovascular-kidney-metabolic (CKM) syndrome: A state-of-the-art review[J]. Curr Probl Cardiol, 2024, 49(2): 102344.doi:10.1016/j.cpcardiol.2023.102344.
[33]	Ma J, Staler DW, Mahato RI. Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment[J]. Med Chem Res, 2024, 33(8): 1339-1353.doi:10.1007/s00044-024-03267-3. pmid: 40801006
[34]	Xiao Y, Wang J, Zhang H, et al. Linarin alleviates high-fat diet-induced hepatic steatosis by inhibiting PDE4D and activating the cAMP/PKA/CREB pathway[J]. Free Radic Biol Med, 2025, 239: 116-129.doi:10.1016/j.freeradbiomed.2025.07.030.
[35]	Tao X, He H, Peng J, et al. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: Therapeutic role of roflumilast[J]. Pharmacol Res, 2022, 175: 106004.doi:10.1016/j.phrs.2021.106004.
[36]	Lian CY, Zhai ZZ, Li ZF, et al. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms[J]. Chem Biol Interact, 2020, 330: 109199.doi:10.1016/j.cbi.2020.109199.
[37]	Tao X, Chen C, Huang Z, et al. Genetic deletion of phosphodiesterase 4D in the liver improves kidney damage in high-fat fed mice: Liver-kidney crosstalk[J]. Cell Death Dis, 2023, 14(4): 273.doi:10.1038/s41419-023-05792-2. pmid: 37072403
[38]	Alisi A, McCaughan G, Grønbæk H. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: Clinical impact[J]. Hepatol Int, 2024, 18(Suppl 2): 861-872.doi:10.1007/s12072-024-10674-6.
[39]	Giordano L, Ahmed S, van der Made TK, et al. Gut microbial-derived short chain fatty acids enhance kidney proximal tubule cell secretory function[J]. Biomed Pharmacother, 2025, 188: 118214.doi:10.1016/j.biopha.2025.118214.
[40]	Lei Y, Xiong G, Lei D, et al. Gut microbiota-derived TMAO drives the kidney-bone-vascular axis in chronic kidney disease complications[J]. Ren Fail, 2025, 47(1): 2575434.doi:10.1080/0886022x.2025.2575434.
[41]	He M, Wei W, Zhang Y, et al. Gut microbial metabolites SCFAs and chronic kidney disease[J]. J Transl Med, 2024, 22(1): 172.doi:10.1186/s12967-024-04974-6. pmid: 38369469
[42]	Miao C, Wang L, Wang H, et al. Lacticaseibacillus plantarum postbiotics prepared by the combined technique of pasteurization and ultrasound: Effective measures to alleviate obesity based on the SCFAs-GPR41/GPR43 signaling pathway[J]. Food Funct, 2024, 15(22): 11005-11019.doi:10.1039/d4fo03591g.
[43]	Carmody RN, Bisanz JE. Roles of the gut microbiome in weight management[J]. Nat Rev Microbiol, 2023, 21(8): 535-550.doi:10.1038/s41579-023-00888-0. pmid: 37138047
[44]	Sun DQ, Zheng KI, Xu G, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels[J]. Liver Int, 2020, 40(1): 107-119.doi:10.1111/liv.14251.
[45]	Mantovani A, Taliento A, Zusi C, et al. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings[J]. Liver Int, 2020, 40(5): 1130-1141.doi:10.1111/liv.14419. pmid: 32125756
[46]	Akuta N, Kawamura Y, Arase Y, et al. PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD[J]. BMC Gastroenterol, 2021, 21(1): 434.doi:10.1186/s12876-021-02020-z. pmid: 34798835
[47]	Mantovani A, Pelusi S, Margarita S, et al. Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction[J]. Aliment Pharmacol Ther, 2023, 57(10): 1093-1102.doi:10.1111/apt.17477.
[48]	Mantovani A, Targher G. PNPLA3 variation and kidney disease[J]. Liver Int, 2025, 45(3): e16010. doi:10.1111/liv.16010.
[49]	Cherubini A, Casirati E, Tomasi M, et al. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date[J]. Expert Opin Ther Targets, 2021, 25(12): 1033-1043.doi:10.1080/14728222.2021.2018418.
[50]	Donati B, Motta BM, Pingitore P, et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage[J]. Hepatology, 2016, 63(3): 787-798.doi:10.1002/hep.28370. pmid: 26605757
[51]	Meroni M, Longo M, Tria G, et al. Genetics is of the essence to face NAFLD[J]. Biomedicines, 2021, 9(10): 1359. doi:10.3390/biomedicines9101359.
[52]	Park J, Zhao Y, Zhang F, et al. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease[J]. J Hepatol, 2023, 78(1): 45-56.doi:10.1016/j.jhep.2022.08.022.
[53]	Chen S, Chen T, Xu C, et al. Iron overload exaggerates renal ischemia-reperfusion injury by promoting tubular cuproptosis via interrupting function of LIAS[J]. Redox Biol, 2025, 86: 103795.doi:10.1016/j.redox.2025.103795.
[54]	Shin JA, Hwang Y, Park H, et al. Renoprotective effects of MIT-001 in ischemia-reperfusion injury: Modulation of ferroptosis, ROS and fibrotic markers[J]. J Cell Mol Med, 2025, 29(20): e70914.doi:10.1111/jcmm.70914.
[55]	Tao L, Yang X, Ge C, et al. Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH[J]. Cell Metab, 2024, 36(10): 2190-2206.e2195.doi:10.1016/j.cmet.2024.07.013. pmid: 39142286
[56]	Zhang J, Wang Y, Fan M, et al. Reactive oxygen species regulation by NCF1 governs ferroptosis susceptibility of Kupffer cells to MASH[J]. Cell Metab, 2024, 36(8): 1745-1763.e1746.doi:10.1016/j.cmet.2024.05.008.
[57]	Corradini E, Buzzetti E, Dongiovanni P, et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD[J]. J Hepatol, 2021, 75(3): 506-513.doi:10.1016/j.jhep.2021.03.014. pmid: 33774058
[58]	Chen IC, Chou LJ, Huang SC, et al. Machine learning-based comparison of factors influencing estimated glomerular filtration rate in Chinese women with or without non-alcoholic fatty liver[J]. World J Clin Cases, 2024, 12(15): 2506-2521.doi:10.12998/wjcc.v12.i15.2506. pmid: 38817230
[59]	Cao Y, Du Y, Jia W, et al. Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning[J]. Front Endocrinol (Lausanne), 2023, 14: 1125829.doi:10.3389/fendo.2023.1125829.
[60]	Fan J, Li N, Lu Y, et al. Identification of key genes in membranous nephropathy and non-alcoholic fatty liver disease by bioinformatics and machine learning[J]. Front Immunol, 2025, 16: 1564288.doi:10.3389/fimmu.2025.1564288.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 60

Related Articles 0

Recommended Articles

Metrics

Comments